Postoperative iodine‐125 interstitial brachytherapy for the early stages of minor salivary gland carcinomas of the lip and buccal mucosa with positive or close margins

Wu, Wenjie; Shao, Xiao; Huang, Mei; Lv, Xianli; Zhang, Xin‐Na; Zhang, Jianguo

doi:10.1002/hed.24659

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an internal RT, iodine-125 seed implantation has been successfully used to treat a series of malignant tumors, such as prostate cancer, 24 brain tumors, 25 , 26 pancreatic cancer, 27 skin cancer, 28 ovarian cancer, 29 recurrent cervical cancer, 30 and head and neck neoplasms, 31 especially in NSCLC. Santos et al indicated that the use of iodine-125 brachytherapy after sublobar resection significantly improved local control compared with sublobar resection alone (18.6 vs 2%; P <0.0001).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Wu¹,

Li²,

Sun³

et al. 2018

OTT

View full text Add to dashboard Cite

BackgroundAdvanced non-small-cell lung cancer (NSCLC) is a huge challenge for physicians. Traditional chemoradiotherapy is associated with high rates of toxicities, especially when treating gerontal patients. Our study was focused on investigating the safety and efficacy of permanent iodine-125 seed implantation and chemotherapy for the treatment of advanced NSCLC in the elderly.MethodsFifty elderly patients with stage III or IV NSCLC at our hospital from January 2011 to June 2017 were treated with the chemotherapy regimens (paclitaxel/cisplatin) and computed tomography (CT)-guided iodine-125 brachytherapy (group A), 50 patients who received chemotherapy consisting of paclitaxel and cisplatin only (group B) were matched-up with the patients in group A. The local response rate was evaluated by CT. Progression-free survival (PFS) and overall survival (OS) data were obtained through clinical follow-up.ResultsThe patients were followed-up for 3–46 months. With a median follow-up time of 20 months, the OS and PFS were 20 months (95% CI: 19.09–20.90 months) vs 15 months (95% CI: 14.48–15.51 months) (P<0.05) and 13 months (95% CI: 11.96–14.04 months) vs 8 months (95% CI: 7.63–8.37 months) (P<0.05) in group A and group B, respectively. The symptoms of patients in group A were significantly relieved when compared with group B. Severe complications were not observed in either of the groups.ConclusionThe combination of iodine-125 seed brachytherapy and chemotherapy is an effective and safe therapy and is superior to chemotherapy alone for advanced NSCLC in the elderly.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Wu¹,

Li²,

Sun³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…External beam radiotherapy may be used to address this. However, in our patient, the tumor was small in size, was located superficially and there was no perineural invasion, so we felt comfortable using brachytherapy [7,8,[15][16][17][18][19]. The patient tolerated the procedure well with only grade two acute mucositis of the soft palate.…”

Section: Treatmentmentioning

confidence: 74%

“…Occasionally, brachytherapy is used in cancer centers with expertise in this modality to minimize toxicity in select cases of oropharyngeal and salivary gland cancers. The radiation dose to the normal tissues can be lowered by this method in select cases [15][16][17]. When tumors are technically accessible and superficially-located, surface mold brachytherapy technique may be utilized in oral and oropharyngeal cancers [7,8,18,19].…”

Section: Introductionmentioning

confidence: 99%

Squamous Cell and Adenoid Cystic Carcinoma Collision Tumor of the Soft Palate Treated with Surface Mold Brachytherapy

Reshko¹,

Khan²,

Sowards³

et al. 2020

Cureus

View full text Add to dashboard Cite

Simultaneous primary cancers are rare in the oropharynx. This report describes the first reported case of a collision tumor of squamous cell and adenoid cystic carcinoma in the soft palate. The patient was immunosuppressed with a history of liver transplantation, smoking and heavy alcohol drinking. He was treated with wide local excision followed by adjuvant radiotherapy with surface acrylic mold brachytherapy. This technique was used instead of external beam radiotherapy in order to minimize toxicity. The patient tolerated the treatment well and with the only acute grade two mucositis at the soft palate and minimal late toxicity. There is no evidence of disease recurrence and the patient continues to maintain excellent quality of speech and swallowing 14 months after treatment completion.

show abstract

“…125 I IBT, as a radiotherapy modality, increases local dose while sparing surrounding normal tissues, which is highly conformal, even for tumors closely surrounded by critical structures. 125 I IBT is increasingly being found to be effective for patients with head and neck malignant tumors and in improving LC and survival rate, so it is being used for pediatric soft‐tissue sarcoma treatment . Laskar et al treated 50 pediatric soft‐tissue sarcomas with brachytherapy as a monotherapy or combined with external radiotherapy.…”

Section: Discussionmentioning

confidence: 94%

¹²⁵I interstitial brachytherapy in management of pediatric skull base tumors

Chen

et al. 2019

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Background The purpose of this study was to present our preliminary assessment of the safety and efficacy of 125I interstitial brachytherapy (IBT) in the management of pediatric skull base tumors. Methods Thirty pediatric patients with skull base tumors treated with 125I IBT from April 2007 to May 2017 were included in this study. The probabilities of local control (LC) and overall survival (OS) were calculated by the Kaplan–Meier method. Results The one‐ and two‐year LC rates were 96.7% and 74.8%, respectively. The one‐ and two‐year OS rates were 93.3% and 72.2%, respectively. No severe acute toxicity was observed. Severe late toxicities were observed in one (3.33%) of 30 patients. Conclusion 125I IBT is effective and safe in the management of pediatric skull base tumors, with satisfactory cosmetic and functional outcomes.

show abstract

Postoperative iodine‐125 interstitial brachytherapy for the early stages of minor salivary gland carcinomas of the lip and buccal mucosa with positive or close margins

Abstract: Postoperative I seed interstitial brachytherapy is an alternative to radical surgery for early stages of minor salivary gland carcinomas of the lip and buccal mucosa, which offers satisfactory cosmetic and functional outcomes. © 2017 Wiley Periodicals, Inc. Head Neck 39: 572-577, 2017.

Cited by 9 publications

References 30 publications

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Squamous Cell and Adenoid Cystic Carcinoma Collision Tumor of the Soft Palate Treated with Surface Mold Brachytherapy

¹²⁵I interstitial brachytherapy in management of pediatric skull base tumors

Contact Info

Product

Resources

About

Postoperative iodine‐125 interstitial brachytherapy for the early stages of minor salivary gland carcinomas of the lip and buccal mucosa with positive or close margins

Abstract: Postoperative I seed interstitial brachytherapy is an alternative to radical surgery for early stages of minor salivary gland carcinomas of the lip and buccal mucosa, which offers satisfactory cosmetic and functional outcomes. © 2017 Wiley Periodicals, Inc. Head Neck 39: 572-577, 2017.

Cited by 9 publications

References 30 publications

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Squamous Cell and Adenoid Cystic Carcinoma Collision Tumor of the Soft Palate Treated with Surface Mold Brachytherapy

125I interstitial brachytherapy in management of pediatric skull base tumors

Contact Info

Product

Resources

About

¹²⁵I interstitial brachytherapy in management of pediatric skull base tumors